GSK plc (GSK)

NYSE: GSK · USD

$48.7

-2.24 (-4.4%)· Recorded snapshot

Market cap	97.9B
Revenue (ttm)	44.5B
Net income (ttm)	5.8B
EPS (ttm)	$3.13
Shares out	4B
P/E (trailing)	15.5x
P/E (forward)	8.9x
Dividend	$1.79 (3.67%)
Volume	7,610,030
Beta	0.28

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 44.5B
Net income (ttm): 5.8B
EPS (ttm): $3.13
P/E (trailing): 15.5x
P/E (forward): 8.9x
Market cap: 97.9B

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Mantener

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/E8.9

P25 n/aP50 n/aP75 n/a

Trailing P/E15.5

P25 n/aP50 n/aP75 n/a

ROE28.3

P25 n/aP50 n/aP75 n/a

ROIC18.8

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All GSK indicators

Market & fundamental data

Available fields

283

Groups with data

Currency

GBP

Showing 283 of 283 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001131399
Company name	GSK plc
Country	United Kingdom
Country code	US
CUSIP number	37733W204
Earnings date	2026-10-28
Earnings time	bmo
Employees	66,841
Employees change	-1,788
Employees growth	-2.61%
Enterprise value	$117.5B
Exchange	NYSE
Financial currency	GBP
Financial report date	2026-09-30
First seen	2026-05-09
Fiscal year end	December
Founded	1715
Industry	Drug Manufacturers - General
Is primary listing	No
Is SPAC	No
ISIN number	US37733W2044
Last 10-K release date	2026-03-06
Last earnings date	2026-10-28
Last refreshed	2026-10-28
Last stock split date	2022-07-19
Last stock split type	Reverse
Market cap	$97.9B
Market cap category	Large-Cap
Next earnings date	2027-02-03
Options	Yes
Price	$48.70
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-28
Symbol	GSK
Website	https://www.gsk.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Adjusted P/E ratio	10.32x
Average P/E ratio (10Y)	21.56x
Average P/E ratio (3Y)	16.33x
Average P/E ratio (5Y)	13.77x
Earnings yield	6.44%
EV/Earnings	21.15x
EV/EBIT	12.24x
EV/EBITDA	9.01x
EV/FCF	12.37x
EV/Sales	2.74x
FCF / EV yield	8.08%
FCF yield	9.63%
Forward EV/Sales	2.62x
Forward P/E	8.92x
Forward P/S	2.2x
Graham number	26.82075
Graham upside	-45.12%
Industry forward P/E	18.47x
Industry P/E	35.8x
Lynch fair value	$13.76
Lynch upside	-71.84%
P/(FCF - SBC) ratio	10.94x
P/(OCF - SBC) ratio	9.02x
P/B ratio	4.21x
P/E ratio	15.53x
P/FCF ratio	10.39x
P/OCF ratio	8.65x
P/S ratio	2.3x
Price/EBITDA ratio	7.57x
Sector forward P/E	23.56x
Sector P/E	50.13x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	22.41%
EBITDA margin	30.44%
Effective tax rate	10.42%
FCF margin	22.13%
Gross margin	72.82%
Operating margin	22.41%
Pretax margin	16.05%
Profit margin	12.97%
Profit per employee	$86,421
Profitable quarters	7
Profitable years	23
Revenue per employee	$666,241
ROA	7.06%
ROA (5Y)	7.23%
ROCE	14.74%
ROE	28.27%
ROE (5Y)	32.1%
ROIC	18.84%
ROIC (5Y)	22.54%
SBC / revenue	1.11%
Tax / revenue	1.67%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth	-19.73%
EPS growth (Q)	-22.81%
EPS growth (QoQ)	254.21%
EPS growth 10Y	30.09%
EPS growth 3Y	-10.34%
EPS growth 5Y	0%
EPS growth years	1
FCF growth	14.66%
FCF growth (Q)	27.42%
FCF growth (QoQ)	3.09%
FCF growth 3Y	20.79%
FCF growth 5Y	1.32%
Gross profit growth	4.83%
Gross profit growth (Q)	3%
Gross profit growth 3Y	5.31%
Gross profit growth 5Y	6.15%
Net income growth	-20.81%
Net income growth (Q)	-23.35%
Net income growth (QoQ)	254.71%
Net income growth 3Y	-10.52%
Net income growth 5Y	0.18%
Net income growth years	1
OCF growth	14.45%
OCF growth (Q)	26.42%
OCF growth (QoQ)	4.42%
OCF growth 10Y	5.94%
OCF growth 3Y	17.65%
OCF growth 5Y	2.09%
Operating income growth	-14.77%
Operating income growth (Q)	-30.99%
Operating income growth 3Y	-0.36%
Operating income growth 5Y	2.77%
Revenue growth	4.28%
Revenue growth (Q)	3.98%
Revenue growth (QoQ)	5.68%
Revenue growth 10Y	2.35%
Revenue growth 3Y	4.2%
Revenue growth 5Y	4.94%
Revenue growth quarters	7
Revenue growth years	5

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-2B
Depreciation and amortization	$3.6B
EBIT	$10B
EBITDA	$13.6B
EPS	$3.13
FCF per share	$2.46
Financing cash flow	$2.6B
Free cash flow	$9.9B
Free cash flow minus SBC	$9.4B
Gross profit	$32.4B
Income taxes	$744.8M
Investing cash flow	$-14.5B
Net borrowing	$8.4B
Net cash flow	$-103.6M
Net income	$5.8B
Operating cash flow minus SBC	$11.4B
Operating income	$10B
Revenue	$44.5B
Stock-based compensation	$496.5M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Book value per share	$6.21
Debt / EBITDA	2.28
Debt / equity	1.29
Debt / FCF	3.19
Goodwill	$10.9B
Interest coverage	10.54
Long-term assets	$71.4B
Long-term liabilities	$43.3B
Net cash (debt)	$-27.5B
Net cash / market cap	-26.85%
Net debt / EBITDA	2.03
Net debt / equity	1.13
Net debt / FCF	2.79
Piotroski F-Score	6
Property, plant and equipment	$13.5B
Shareholders' equity	$24.4B
Tangible book value	$-19.4B
Tangible book value per share	$-4.85
Total assets	$95.2B
Total cash	$3.9B
Total debt	$31.5B
Total liabilities	$70.8B
WACC	5.06%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.5
Current assets	$23.8B
Current liabilities	$27.6B
Current ratio	0.86
Inventory turnover	1.47
Net working capital	$-5B
Quick ratio	0.55
Working capital	$-3.8B
Working capital turnover	-14.1

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	1.41%
Dividend growth	10.29%
Dividend growth (10Y)	-4.01%
Dividend growth (3Y)	9.74%
Dividend growth (5Y)	-7.99%
Dividend growth years	2
Dividend payment date	2026-10-08
Dividend payment years	54
Dividend payout frequency	Quarterly
Dividend per share	$1.79
Dividend yield	3.67%
Ex-dividend date	2026-08-14
FCF payout ratio	72.55%
Last dividend	$0.44
Payout ratio	57.01%
Shareholder yield	5.07%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y price change	-3.69%
10Y return CAGR	6.44%
10Y total return	86.6%
150-day SMA	$51.56
15Y price change	-13.01%
15Y return CAGR	5.45%
15Y total return	121.7%
1D price change	-4.4%
1M price change	-1.18%
1M total return	-1.18%
1W price change	-3.89%
1W total return	-3.89%
1Y price change	11.1%
1Y return CAGR	14.98%
1Y total return	14.97%
20-day SMA	$48.49
200-day SMA	$52.36
20Y price change	-26.94%
20Y return CAGR	4.41%
20Y total return	136.88%
3M price change	-6.39%
3M total return	-5.56%
3Y price change	40.8%
3Y return CAGR	16.48%
3Y total return	58.05%
50-day SMA	$49.56
50-day SMA vs 200-day SMA	50under200
52-week high	$61.70
52-week high date	2026-02-18
52-week low	$42.89
52-week low date	2025-10-28
5Y price change	-3.69%
5Y return CAGR	7.61%
5Y total return	44.26%
6M price change	-10.25%
6M total return	-8.66%
All-time high	$74.98
All-time high date	2007-04-20
All-time low	$28.47
All-time low date	2022-09-26
Average true range (ATR)	$1.16
Average volume	5.9M
Beta (5Y)	0.28
Change from 52-week high	-21.06%
Change from 52-week low	13.56%
Change from all-time high	-35.1%
Change from all-time low	70.95%
Change from open	2.46%
Day's gap	-6.69%
Dollar volume	$370.6M
High price	$49.31
Low price	$47.37
Monthly RSI	53.76
Open price	$47.53
Position in 52-week range	68.56%
Premarket change	-6.32%
Premarket close	$50.94
Premarket price	$47.72
Premarket volume	992.1K
Previous close	$50.94
Price vs 150-day SMA	-5.62%
Price vs 20-day SMA	0.35%
Price vs 200-day SMA	-7.06%
Price vs 50-day SMA	-1.82%
Relative volume	1.29
RSI	46.46
Sharpe ratio	0.51
Sharpe ratio (3Y)	0.52
Sharpe ratio (5Y)	0.28
Sortino ratio	1.03
Sortino ratio (3Y)	1
Sortino ratio (5Y)	0.64
Volume	7.6M
Weekly RSI	46.2
YTD price change	-0.77%
YTD total return	1.78%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	3.9B
Float percentage	96.9%
Shares change (QoQ)	0.23%
Shares change (YoY)	-1.41%
Shares held by insiders	0.06%
Shares held by institutions	84.57%
Shares outstanding	4B
Short % of shares	0.74%
Short ratio	4.8 days

Other indicators

Additional ticker metrics that do not fit the primary research groupings.

Metric	Value
Page views	293

Deeper analysis on GSK

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this GSK report

Is a complete GSK research report available?

No complete published report is available for GSK plc (GSK) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

GSK plc (GSK)

Price

Financial snapshot

Fair-value bridge

Latest news · GSK

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All GSK indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Other indicators

Deeper analysis on GSK

Frequently asked questions